NCOG-24. TIME TO FIRST RECURRENCE AND SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA

Abstract INTRODUCTION Time to recurrence is a source of considerable anxiety in glioblastoma. Assuming survival certain timepoint without tumor progression, how do odds/outcomes change relative initial starting conditions? Is there single with highest risk after which "the longer you go, the go"? METHODS Newly-diagnosed glioblastomas were retrospectively reviewed (n=209). Pre-2012 diagnoses (n=2) & IDH-mutants excluded (n=8). Median PFS/OS and remaining time mPFS calculated for sub-populations disease progression (POD) at 0, 3, 6, 8, 12, 24 months post-surgery. RESULTS 199 IDH-wildtype identified -- 40% women, median age 63 years (range 26-91), 43% gross-total resection, 65% MGMT unmethylated, upfront RT 60Gy (23% 40Gy) 8 / mOS 19 months. Patients POD within 3 had 20 Outcomes progressively improve later timepoints-- 10/13/20/39 23/27/39/65 months, patients 6/8/12/24 post-surgery respectively. comprised 10% original cohort (n=20; deaths). As surrogate was (taken as difference between question, population up that timepoint) followed J-shape curve (at 0 post-surgery), 4 (for 6 7-8 10-14 13 15 18 post-surgery, respectively). DISCUSSION Sub-populations early appear have improved baseline, has implications clinical trials internal controls. Nevertheless, seems be it appears go."